Trial Profile
AFX01-13: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Correction of Anemia in Patients With Chronic Renal Failure (CRF) Not on Dialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Peginesatide (Primary) ; Darbepoetin alfa
- Indications Anaemia
- Focus Therapeutic Use
- Acronyms PEARL 2
- Sponsors Affymax
- 26 May 2014 New trial record